Work

Harnessing Immune Responses in the Tumor Microenvironment: All Signals Needed

Year: 2013

Type: article

Abstract: An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-13-2424

Authors: Dung T. Le, Elizabeth M. Jaffee

Institution: Johns Hopkins University

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute